	OIPE					Sheet 1	_ of _	2_	
Form PTO	-1449 U.S.	PARTMENT OF	F COMMERCE	ATTY. DOCKET NO.		SERIAL NO.	01 421		
	D JAN 3 1 2002 PA	ENT AND TRAL	JEMARK OFFICE	3086-A		09/9	81,421		
INFOR	MARQN DISCL	SURE CIT	ATION	APPLICANT	1				
	RADENARI			John E. Sims et a	1. 	GROUP			
(	Use several sheets if	î necessarv	)	October 17, 200	01		632		
			<del> </del>						
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE	
アタ	5,776,731	07/07/98	Parnet et al.						
1	5,912,324	06/15/99	Okamura et	t al					
	6,060,283	05/09/00	Okura et al.						
V	6,087,116	07/11/00	Torigoe et a	al.			,.	· .	
·		FO	REIGN PATE	NT DOCUMENTS					
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NO	
D8	WO 99/09063	02/25/99	PCT						
1	WO 99/19480	04/22/99	PCT				,		
	WO 99/37772	07/29/99	PCT				-		
	WO 99/37773	07/29/99	PCT				4 (1) 2001	7 F	
	WO 00/18800	04/06/00	PCT						
	WO 00/56771	09/28/00	PCT						
V	WO 01/07480 A2	02/01/01	PCT						
	OTHER DOC	UMENTS (	Including Auth	or, Title, Date, Pertinent	Pages,	Etc.)			
DY	Dayer, "Interleul 104(10):1337-13	kin-18, rhe 39, 1999	umatoid arth	ritis, and tissue destr	ruction,	," J. Clin. Ir			
	Debets et al., "II	-18 Recep	tors, Their R	Role in Ligand Bindin	ng and	Function: A	nti-IL-		
	1RAcPL Antibody, a Potent Antagonist of IL-18," J. Immunol. 165:4950-4956, 2000  Gracie et al., "A proinflammatory role for IL-18 in rheumatoid arthritis," J. Clin. Invest.								
	104(10):1393-1401, 1999								
	Leung et al., "Combined Effects of IL-12 and IL-18 on the Induction of Collagen-Induced Arthritis," J. Immunol. 164:6495-6502, 2000								
_				ression is Up-Regula	ated in	Crohn's Dis	sease "		
	Immunol. 163:14						, ouse,	· · · · · · · · · · · · · · · · · · ·	
	Nakanishi et al., "Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2								
	responses depending on its cytokine milieu," Cytokine Growth Factor Review 12(1):53-72, 2001								
		8 is Produ	ced by Artici	ular Chondrocytes ar	nd Indu	ces Proinfla	ımmato	ry	
$\sqrt{}$				<i>162</i> :1096-1100, 199					
				DATE CONSIDERED					
EXAMINER D	ong n	lina	e e	1( /	101	10K		<u>.</u>	
*EXAMINER: I	nitial if offation considere	d, whether of	not citation is	in conformance with MPE	P 609;	Draw line thro	ugh citat	ion if	
not in confor	mance and not considere	ed. Include o	opy of this forn	n with next communication	n to app	licant.			

· ·	70							
Form PTO		EPARTMENT OF CO		ATTY, DOCKET NO.		SERIAL NO.	21 121	
	JAN 3 1 2002 📆	ENT AND TRADEM	ARK OFFICE	3086-A		09/98	81,421	
INFOR	MALION DISCLAS	SURE CITA	TION	APPLICANT				
	AND ENLER			John E. Sims et a			·	
			FILING DATE	ROUP				
(	Use several sheets if			October 17, 200	<u> </u>	10	532	
	<del></del>	<u></u>	S. PATENT	DOCUMENTS		<del>-1</del>		
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
					<b> </b>			
					ļ			
					<u></u>			
		FORE	IGN PATE	NT DOCUMENTS			· · ·	
•	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATIO YES N	
DY	WO 01/62285 A1	08/30/01 P	СТ					
1	EP 0 850 952 A1	07/01/98 E	urope					
	EP 0 861 663 A2	09/02/98 E	urope					
	EP 0 864 585 A1	09/16/98 E	urope					
	EP 0 974 600 A2	01/26/00 E	urope					
	EP 1 101 772 A1	05/23/01 E	urope				1 1.7	
V	EP 1 110 969 A1	06/27/01 E	urope					
		UMENTS (Inc	luding Auth	or, Title, Date, Pertinent	Pages.	Etc.)		
D)	Pizarro et al., "II	L-18, a Novel	Immunor	regulatory Cytokine, n Intestinal Mucosal	is Up-F	Regulated in		
1	Saha et al., "Inte			Enzyme/Caspase-1: 0:1577-1587, 1999	in Hum	an Osteoart	hritic	
	Ushio et al., "Cle Escherichia coli 156:4274-4279,	oning of the o , and Studies 1996	DNA for on the Bio	Human IFN-γ-Induc ologic Activities of t	he Prote	ein," <i>J. Imm</i>	unol.	
<b>√</b>				and Susceptibility to 18-Deficient Mice,",				
J	ong )	ian	R_	DATE CONSIDERED	11	119 to	4	
EXAMINER	00		7					
*EYAMINER: I	nitial if citation considere	d whether or no	at citation is	in conformance with MDI	ED 600.	Draw line thro	uph citation if	

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.